To include your compound in the COVID-19 Resource Center, submit it here.

GI-4000: Phase IIa data

An open-label Phase IIa trial in 24 patients with tumors expressing K-Ras mutations showed that consolidation

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE